Rapamycin passes the torch: a new generation of mTOR inhibitors
- PMID: 22037041
- DOI: 10.1038/nrd3531
Rapamycin passes the torch: a new generation of mTOR inhibitors
Abstract
Mammalian target of rapamycin (mTOR) is an atypical protein kinase that controls growth and metabolism in response to nutrients, growth factors and cellular energy levels, and it is frequently dysregulated in cancer and metabolic disorders. Rapamycin is an allosteric inhibitor of mTOR, and was approved as an immuno-suppressant in 1999. In recent years, interest has focused on its potential as an anticancer drug. However, the performance of rapamycin and its analogues (rapalogues) has been undistinguished despite isolated successes in subsets of cancer, suggesting that the full therapeutic potential of targeting mTOR has yet to be exploited. A new generation of ATP-competitive inhibitors that directly target the mTOR catalytic site display potent and comprehensive mTOR inhibition and are in early clinical trials.
Similar articles
-
mTOR kinase inhibitors as a treatment strategy in hematological malignancies.Future Med Chem. 2012 Mar;4(4):487-504. doi: 10.4155/fmc.12.14. Future Med Chem. 2012. PMID: 22416776 Review.
-
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.Biochem Soc Trans. 2011 Apr;39(2):456-9. doi: 10.1042/BST0390456. Biochem Soc Trans. 2011. PMID: 21428919 Review.
-
Updates of mTOR inhibitors.Anticancer Agents Med Chem. 2010 Sep;10(7):571-81. doi: 10.2174/187152010793498663. Anticancer Agents Med Chem. 2010. PMID: 20812900 Free PMC article. Review.
-
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. Expert Opin Investig Drugs. 2010. PMID: 20569080 Review.
-
Targeting mTOR signaling pathway in ovarian cancer.Curr Med Chem. 2011;18(19):2960-8. doi: 10.2174/092986711796150450. Curr Med Chem. 2011. PMID: 21651485 Review.
Cited by
-
Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies.Front Oncol. 2021 Feb 25;11:626309. doi: 10.3389/fonc.2021.626309. eCollection 2021. Front Oncol. 2021. PMID: 33718194 Free PMC article. Review.
-
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Oncotarget. 2012 Oct;3(10):1068-111. doi: 10.18632/oncotarget.659. Oncotarget. 2012. PMID: 23085539 Free PMC article. Review.
-
Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer.Cancers (Basel). 2024 Jun 18;16(12):2259. doi: 10.3390/cancers16122259. Cancers (Basel). 2024. PMID: 38927964 Free PMC article. Review.
-
Pharmaceutical inhibition of mTOR in the common marmoset: effect of rapamycin on regulators of proteostasis in a non-human primate.Pathobiol Aging Age Relat Dis. 2016 Jun 23;6:31793. doi: 10.3402/pba.v6.31793. eCollection 2016. Pathobiol Aging Age Relat Dis. 2016. PMID: 27341957 Free PMC article.
-
mTORC1-Induced HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation.Cell Rep. 2015 Jul 7;12(1):102-115. doi: 10.1016/j.celrep.2015.05.046. Epub 2015 Jun 25. Cell Rep. 2015. Retraction in: Cell Rep. 2023 Jun 27;42(6):112639. doi: 10.1016/j.celrep.2023.112639 PMID: 26119735 Free PMC article. Retracted.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous